Table 2 Results from testing the association between polygenic risk scores based on UK data, and a phenotype status, based on Icelandic data

From: Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA

PRSs

Phenotype

Effect (β)

P-value

PSA_increase/PRS_SD (%)

95% c.i. (%)

(a) Separately

     

 PC

PSA levels

0.089

9.8 × 10−68

16.3

(14.3, 18.3)

 BPH/LUTS

PSA levels

0.071

6.0 × 10−45

12.9

(10.9, 14.8)

(b) Jointly

     

 PC

PSA levels

0.074

4.1 × 10−43

13.3

(11.3, 15.3)

 BPH/LUTS

PSA levels

0.049

3.0 × 10−20

8.6

(6.7, 10.5)

  1. Shown are results from testing the association of polygenic genetic risk scores (PRSs), based on effect estimates from the UK for: prostate cancer (PC) and benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), for correlation with serum levels of PSA (PSA levels) in 18,929 Icelandic males. Shown are the effect estimates (β), the two-sided P-values calculated using logistic regression in R (v3.5), the percentage increase in PSA levels for each standard deviation (SD) increase in the PRSs, and the 95% confidence intervals (c.i.)
  2. In section a the results are shown separately for the PRSs of prostate cancer (PC) and BPH/LUTS, whereas in section b the results are shown jointly (i.e. after being conditioned for each other)
Back to article page